EP3578169
LYFJASAMSETNINGAR SEM INNIHALDA 4-{(1 R)-2-[(6-{2-[(2,6-DÍKLÓRÓBENSÍL)OXÝ]ETOXÝ}HEXÝL)AMÍNÓ]-1- HÝDROXÝETÝL}-2-(HÝDROXÝMETÝL)FENÓL
- :EP einkaleyfi í gildi á Íslandi
- :26.2.2009
- :26.6.2024
- :19175120.5
- :29.8.2024
- :15.10.2024
- :25.2.2029
- :25.2.2026
- :28.2.2026
- :PHARMACEUTICAL FORMULATIONS COMPRISING 4-{(1 R)-2-[(6-{2-[(2,6-DICHLOROBENZYL)OXY]ETHOXY}HEXYL)AMINO]-1-HYDROXYETHYL}-2-(HYDROXYMETHYL)PHENOL
26.2.2009
26.6.2024
29.8.2024
15.10.2024
25.2.2026
- :Glaxo Group Limited
- :GSK Medicines Research Centre Gunnels Wood Road, Stevenage SG1 2NY, GB
- :BAKER, Darrell
- :Uxbridge, Middlesex UB11 1BT, GB
- :BRUCE, Mark
- :Stevenage, Hertfordshire SG1 2NY, GB
- :THOMAS, Marian
- :Ware, Hertfordshire SG12 ODP, GB
- :Zacco Denmark A/S
- :Arne Jacobsens Allé 15, DK
- :A61K 9/00, A61K 31/58, A61K 31/138, A61K 45/06, A61P 11/00, A61P 11/06, A61P 11/08, A61P 37/08, A61P 43/00
: 17
: 29.1.2025
: 25.2.2026
: Árnason Faktor ehf.